[go: up one dir, main page]

AR036873A1 - Piridinas aril sustituidas a, composiciones farmaceuticas y el uso de las mismas para la preparacion de un medicamento - Google Patents

Piridinas aril sustituidas a, composiciones farmaceuticas y el uso de las mismas para la preparacion de un medicamento

Info

Publication number
AR036873A1
AR036873A1 ARP020103214A ARP020103214A AR036873A1 AR 036873 A1 AR036873 A1 AR 036873A1 AR P020103214 A ARP020103214 A AR P020103214A AR P020103214 A ARP020103214 A AR P020103214A AR 036873 A1 AR036873 A1 AR 036873A1
Authority
AR
Argentina
Prior art keywords
formula
optionally substituted
group
alkyl
amino
Prior art date
Application number
ARP020103214A
Other languages
English (en)
Original Assignee
Euro Celtique Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euro Celtique Sa filed Critical Euro Celtique Sa
Publication of AR036873A1 publication Critical patent/AR036873A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

Piridinas aril sustituidas A que tienen la fórmula I: o una sal, profármaco o solvato farmacéuticamente aceptable del mismo, en donde: Ar se selecciona entre el grupo que consiste en Ar1, Ar2, Ar3, y Ar4 en donde Ar1 es fórmula (2), Ar2 es fórmula (3), Ar3 es fórmula (4) y Ar4 es fórmula (5) R1 se selecciona entre el grupo que consiste en un alquilo opcionalmente sustituido, amino, alquiltiol, C(O)R10, SO2R10 y OC(O)NH2; R2 es -Ym-(CH2)n-Z, en donde Y es O, S o NR11, en donde R11 es hidrógeno o alquilo, Z es un anillo heterocíclico saturado opcionalmente sustituido en uno o más átomos de carbono, m es 0 o 1, y n es 0-6; R3 y R4 se seleccionan en forma independiente entre el grupo que consiste en hidrógeno, alquilo, alquenilo, o alquinilo opcionalmente sustituido, halógeno, hidroxi, cicloalquilo, ciano, amino, alquilamino, dialquilamino, alcoxi, aminocarbonilo, alquilaminocarbonilo, arilaminocarbonilo, aralquilaminocarbonilo, alquilcarbonilamino, arilcarbonilamino y aralquilcarbonilamino; R5 R6 R7 y R8 se seleccionan en forma independiente entre el grupo que consiste en hidrógeno, alquilo, alquenilo, alquinilo, halógeno, haloalquilo, hidroxialquilo, hidroxi, nitro, amino, ciano, amida corboxialquilo alcoxialquilo, ureído acilamino, tiol, aciloxi, azido, alcoxi, carboxi, carbonilamido y alquiltiol; R9 es un alquilo opcionalmente sustituido; R10 se selecciona entre el grupo que consiste en alquilo, alquenilo, alquinilo, OR12, amino, alquilamino, dialquilamino, alquenilamino, dialquilaminoalquenilo, dialquilaminoalquilamino, dialquilaminoalquenilamino, alquilaminoalquenilamino, hidroxiaminoalquenilamino, ciclolaquilo, heterocicloalquilo, cicloalquilalquilamino, arilo, arilalquilo, arilalquenilo, arilalquinilo y arilalquilamino, todos los cuales pueden ser opcionalmente sustituidos, siempre y cuando que R10 no sea OR12 cuando R1 es SO2R10; en donde R12 se selecciona entre el grupo que consiste en hidrógeno, alquilo opcionalmente sustituido y un metal alcalino; y x es uno de O, S, NH o CH2 cuando Ar es Ar1; o X es uno de O, S, NH o está ausente (un enlace covalente) cuando Ar es Ar4, con la condición de que cuando Ar es Ar4 y R1 no es C(O)R10 SO2R10 u OC(O)NH2, entonces n no es 0(cero). Además está dirigida a composiciones farmacéuticas y a la utilización de compuestos de la Fórmula (1) para la elaboración de un medicamento para el tratamiento de dano neuronal como consecuencia de isquemia global y focal, para el tratamiento o prevención de condiciones neurodegenerativa tales como esclerosis lateral amiotrófica (ELA) y para el tratamiento, prevención o mejoría tanto de dolor agudo como crónico, incluyendo neuropatía diabética, como agentes antitinnitus, como anticonvulsivos, y como depresivos antimaníacos, como anestésicos locales, como antiarrítmicos.
ARP020103214A 2001-09-07 2002-08-27 Piridinas aril sustituidas a, composiciones farmaceuticas y el uso de las mismas para la preparacion de un medicamento AR036873A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US31745501P 2001-09-07 2001-09-07

Publications (1)

Publication Number Publication Date
AR036873A1 true AR036873A1 (es) 2004-10-13

Family

ID=23233727

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020103214A AR036873A1 (es) 2001-09-07 2002-08-27 Piridinas aril sustituidas a, composiciones farmaceuticas y el uso de las mismas para la preparacion de un medicamento

Country Status (12)

Country Link
US (1) US6770661B2 (es)
EP (1) EP1432424A1 (es)
JP (1) JP2005501916A (es)
KR (1) KR20040074973A (es)
AR (1) AR036873A1 (es)
BR (1) BR0212327A (es)
CA (1) CA2459531A1 (es)
HU (1) HUP0500138A3 (es)
IL (1) IL160714A0 (es)
MX (1) MXPA04002172A (es)
RU (1) RU2004110725A (es)
WO (1) WO2003022285A1 (es)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04000411A (es) * 2001-07-16 2004-03-18 Euro Celtique Sa Tiazolidinonas arilo sustituidas y uso de las mismas.
SI1483247T1 (sl) * 2002-03-13 2009-12-31 Euro Celtique Sa Arilno substituirani pirimidini in njihova uporaba
EP1532119A2 (en) * 2002-07-31 2005-05-25 Euro-Celtique S.A. Aryl substituted benzimidazoles and their use as sodium channel blockers
US20040152696A1 (en) * 2002-08-01 2004-08-05 Euro-Celtique S.A. 2-substituted bicyclic benzoheterocyclic compounds and their use as sodium channel blockers
US20050227974A9 (en) * 2002-08-01 2005-10-13 Euro-Celtique S.A. Aminoalkyl-substituted aryl compounds and their use as sodium channel blockers
WO2004014902A2 (en) * 2002-08-09 2004-02-19 Astrazeneca Ab Compounds having an activity at metabotropic glutamate receptors
US7687080B2 (en) * 2002-11-25 2010-03-30 Taraxos Inc. Treatment of neuropathy
GB0307918D0 (en) * 2003-04-05 2003-05-14 Astrazeneca Ab Therapeutic use
JP4441328B2 (ja) * 2004-05-25 2010-03-31 株式会社ルネサステクノロジ 半導体装置及びその製造方法
US7649004B2 (en) 2004-07-23 2010-01-19 Pfizer, Inc. Pyridine derivatives
RU2007110731A (ru) 2004-09-23 2008-10-27 Редди Юс Терапевтикс Новые соединения пиримидина, способ их получения и содержащие их композиции
US8168592B2 (en) * 2005-10-21 2012-05-01 Amgen Inc. CGRP peptide antagonists and conjugates
GEP20125379B (en) 2007-05-03 2012-01-10 Pfizer Ltd 2 -pyridine carboxamide derivatives as sodium channel modulators
CN102223791A (zh) * 2008-09-27 2011-10-19 塔阿克斯有限公司 用于神经病变治疗的局部用制剂
CN102186824B (zh) * 2008-10-15 2014-03-12 橘生药品工业株式会社 稠环衍生物及其医药用途
WO2011145062A1 (en) 2010-05-21 2011-11-24 Link Research & Grants Corporation Treatment of tinnitus and related auditory dysfunctions
US9120752B2 (en) 2010-07-16 2015-09-01 Purdue Pharma, L.P. Pyridine compounds as sodium channel blockers
AU2011303597A1 (en) * 2010-09-17 2013-04-11 Purdue Pharma L.P. Pyridine compounds and the uses thereof
WO2012042314A1 (en) 2010-10-02 2012-04-05 Link Research & Grants Corporation Treatment of tinnitus and related auditory dysfunctions
MX2013003923A (es) 2010-10-05 2013-07-12 Purdue Pharma Lp Compuestos de quinazolina como bloqueadores del canal de sodio.
KR20130119964A (ko) 2010-12-22 2013-11-01 퍼듀 퍼머 엘피 나트륨 채널 차단제로서의 치환된 피리딘
EP2753606B1 (en) 2011-09-02 2017-07-05 Purdue Pharma LP Pyrimidines as sodium channel blockers
AU2012321111A1 (en) 2011-10-31 2013-05-16 Purdue Pharma L.P. Quaternized amines as sodium channel blockers
US9181185B2 (en) 2011-10-31 2015-11-10 Purdue Pharma L.P. Heteroaryl compounds as sodium channel blockers
US9133131B2 (en) 2011-11-15 2015-09-15 Purdue Pharma L.P. Pyrimidine diol amides as sodium channel blockers
US9206127B2 (en) 2012-03-16 2015-12-08 Purdue Pharm, L.P. Substituted pyridines as sodium channel blockers
WO2013161929A1 (ja) * 2012-04-26 2013-10-31 塩野義製薬株式会社 ピリジニルモルホリノン誘導体およびそれらを含有する医薬組成物
US9714252B2 (en) 2012-12-20 2017-07-25 Purdue Pharma L.P. Cyclic sulfonamides as sodium channel blockers
US9120786B2 (en) 2013-03-04 2015-09-01 Purdue Pharma, L.P. Triazine carboxamides as sodium channel blockers
WO2014135955A1 (en) 2013-03-04 2014-09-12 Purdue Pharma L.P. Pyrimidine carboxamides as sodium channel blockers
WO2014151393A2 (en) 2013-03-15 2014-09-25 Purdue Pharma L.P. Carboxamide derivatives and use thereof
TN2015000547A1 (fr) 2013-06-27 2017-04-06 Pfizer Composes heteroaromatiques et leur utilisation comme ligands de dopamine d1
US9359330B2 (en) 2013-08-26 2016-06-07 Purdue Pharma L.P. Substituted piperidines as sodium channel blockers
EP3039019B1 (en) 2013-08-26 2020-04-22 Purdue Pharma L.P. Azaspiro[4.5]decane derivatives and use thereof
US9828348B2 (en) 2013-11-08 2017-11-28 Purdue Pharma L.P. Benzimidazole derivatives and use thereof
US9340504B2 (en) 2013-11-21 2016-05-17 Purdue Pharma L.P. Pyridine and piperidine derivatives as novel sodium channel blockers
WO2015094443A1 (en) 2013-12-20 2015-06-25 Purdue Pharma L.P. Pyrimidines and use thereof
US9834543B2 (en) 2013-12-23 2017-12-05 Purdue Pharma L.P. Indazoles and use thereof
US9695144B2 (en) 2013-12-23 2017-07-04 Purdue Pharma L.P. Dibenzazepine derivatives and use thereof
EP3089978B1 (en) 2013-12-30 2018-08-29 Purdue Pharma L.P. Pyridone-sulfone morphinan analogs as opioid receptor ligands
WO2015112801A1 (en) 2014-01-24 2015-07-30 Purdue Pharma L.P. Pyridines and pyrimidines and use thereof
CN106103422B (zh) 2014-02-12 2020-09-18 普渡制药公司 异喹啉衍生物及其用途
US10730866B2 (en) 2014-04-07 2020-08-04 Purdue Pharma L.P. Indole derivatives and use thereof
JP6386088B2 (ja) 2014-05-06 2018-09-05 パーデュー、ファーマ、リミテッド、パートナーシップ ベンゾモルファン類似体及びその使用
MA40171A (fr) 2014-06-13 2017-04-19 Purdue Pharma Lp Dérivés d'azamophinan et leur utilisation
WO2015192039A1 (en) 2014-06-13 2015-12-17 Purdue Pharma L.P. Heterocyclic morphinan derivatives and use thereof
CA2977367A1 (en) 2015-02-19 2016-08-25 Purdue Pharma L.P. Methods and compositions for decreasing gastric emptying
WO2017210371A2 (en) * 2016-05-31 2017-12-07 Human Biomolecular Research Institute Compounds as inhibitors of sodium channels

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3149109A (en) * 1962-02-20 1964-09-15 Searle & Co Certain 4-trifluoromethyl-2-(oxy/thio) pyrimidines
FR1477021A (fr) 1965-04-21 1967-04-14 Ilford Ltd Matières photographiques
GB1121922A (en) * 1966-06-17 1968-07-31 Ici Ltd Pyrimidine derivatives
FR1536093A (fr) 1966-09-10 1968-08-09 Basf Ag Nouvelles amino-4-alcoylmercapto-6-triazines-s
US3631036A (en) * 1969-11-04 1971-12-28 American Home Prod 5-amino-2 6-substituted-7h-pyrrolo(2 3-d) pyrimidines and related compounds
US3709888A (en) * 1970-06-01 1973-01-09 Sandoz Ag Aryl-substituted-pyrido(2,3-d)pyrimidin-2-ones
US3660414A (en) * 1970-06-01 1972-05-02 Sandoz Ag Certain 5-aryl-2-amino-nicotinonitriles
US3940404A (en) * 1974-03-06 1976-02-24 The United States Of America As Represented By The Secretary Of The Army 2-Substituted phenyl-6-trifluoromethyl-4-pyridyl-carbinolamines
US3886167A (en) * 1974-03-06 1975-05-27 Us Army 2-Aryl-6-trifluoromethyl-4-pyridylcarbinolamine antimalarials
DE2643753A1 (de) * 1976-09-29 1978-04-06 Thomae Gmbh Dr K Neue 1h-pyrazolo eckige klammer auf 3,4-b eckige klammer zu pyridine
US4133956A (en) * 1977-07-27 1979-01-09 Eli Lilly And Company Preparation of benzoylureas
US4293552A (en) * 1978-02-27 1981-10-06 Eli Lilly And Company Novel 1-(mono-o-substituted benzoyl)-3-(substituted pyrazinyl) ureas
IL59748A (en) 1979-04-05 1983-11-30 Lilly Industries Ltd 5-substituted pyranone derivatives,their production and pharmaceutical compositions containing them
JPS56104883A (en) 1980-01-25 1981-08-20 Tanabe Seiyaku Co Ltd Novel pyridinecarboxamide derivative and its preparation
JPS56115784A (en) * 1980-02-15 1981-09-11 Tanabe Seiyaku Co Ltd Novel pyridinecarboxamide derivative and its preparation
US4769462A (en) * 1980-06-02 1988-09-06 American Cyanamid Co. Novel 2-carbamoylnicotinic and 3-quinolinecarboxylic acids and esters
GB2095240A (en) 1981-03-05 1982-09-29 Fujisawa Pharmaceutical Co Dihydropyrimidine derivatives, processes for preparation thereof and pharmaceutical composition comprising the same
DE3245950A1 (de) 1981-12-24 1983-07-07 Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz Verfahren zur herstellung substituierter pyridine
DE3379544D1 (en) 1982-06-08 1989-05-11 Ciba Geigy Ag 2-phenyl-2-naphthyl and 2-heterocyclic pyrimidines as antidotes for protecting cultured plants before phytotoxic damages caused by herbicides
EP0123700A1 (de) 1983-04-27 1984-11-07 Byk Gulden Lomberg Chemische Fabrik GmbH Substituierte Picolinsäuren, Verfahren zu ihrer Herstellung, ihre Verwendung und sie enthaltende Arzneimittel
US4701208A (en) * 1983-08-02 1987-10-20 American Cyanamid Company Dihydroimidazopyrrolopyridine, quinoline, thieno- and furo[2,3-b]pyridine, dihydrothieno- and furo[2,3-b]-pyridine, thieno- and furo[3,2-b]pyridine and dihydrothieno- and furo[3,2-b]pyridine herbicides and method for preparation thereof
DE3685840D1 (de) 1985-04-30 1992-08-06 Dresden Arzneimittel 3-cyan-pyridine, verfahren zu ihrer herstellung und ihre pharmazeutische verwendung.
JPS6320234A (ja) 1986-07-11 1988-01-27 Daihatsu Motor Co Ltd 自動車の２輪・４輪駆動切換装置
PH23565A (en) * 1986-09-05 1989-08-25 Sumitomo Chemical Co Novel pyrimidinylpyrimidine derivatives and a plant disease protectant containing them as the active ingredient
GB8627059D0 (en) 1986-11-12 1986-12-10 Cookson Group Plc Substituted trialine derivatives
ZW21687A1 (en) * 1986-12-12 1988-07-20 Hoffmann La Roche Triazine derivatives
US5116989A (en) * 1987-11-06 1992-05-26 Baxter Diagnostics Inc. Fluorescent poly(arylpyridine) rare earth chelates
US5084462A (en) * 1988-04-26 1992-01-28 The Du Pont Merck Pharmaceutical Company 4-quinoline carboxylic acid derivatives useful as immunosuppressive agents
ES2040936T3 (es) * 1988-07-13 1993-11-01 Canon Kabushiki Kaisha Composicion de cristal liquido ferroelectrico quiral esmetico y un dispositivo de cristal liquido que utiliza la composicion de cristal liquido.
JPH0252360A (ja) 1988-08-15 1990-02-21 Fujitsu Ltd 電子写真感光体
EP0362578A1 (en) 1988-09-14 1990-04-11 E.I. Du Pont De Nemours And Company Treatment of cancer in mammals by concurrent administration of 4-quinoline carboxylic acid derivatives and interleukin-2
US4968702A (en) * 1989-01-17 1990-11-06 American Cyanamid Company Substituted quinolinecarboxylic acids
GB8906470D0 (en) 1989-03-21 1989-05-04 Cookson Group Plc Photopolymerisable composition
DE3940476A1 (de) * 1989-12-07 1991-06-13 Bayer Ag Pyridinylpyrimidin-derivate
US5403934A (en) * 1990-03-12 1995-04-04 Burroughs Wellcome Co. Heterocyclic compounds
EP0446604A3 (en) 1990-03-16 1992-02-19 American Cyanamid Company Pyridine and related aza heterocycle derivatives as cardiovascular agents
CA2091989A1 (en) 1990-09-28 1992-03-29 Roderick Alan Porter Phenylpyridinol derivatives as medicaments
US5187481A (en) 1990-10-05 1993-02-16 Hewlett-Packard Company Combined and simplified multiplexing and dithered analog to digital converter
DE4032147A1 (de) 1990-10-10 1992-04-16 Bayer Ag Verwendung von substituierten 2-mercaptonicotinsaeurederivaten zur bekaempfung von endoparasiten, neue substituierte 2-mercaptonicotinsaeurederivate und verfahren zu ihrer herstellung
DE69132635T2 (de) 1990-10-25 2001-09-20 Ihara Chemical Industry Co., Ltd. Picolinsäurederivat, seine herstellung und verwendung als herbizid
JPH0597706A (ja) 1991-04-09 1993-04-20 Chemex Block Drug Jv アフタ性潰瘍および他の粘膜皮膚障害の処置方法
GB9124578D0 (en) 1991-11-20 1992-01-08 Smithkline Beecham Plc Chemical compounds
US5389632A (en) * 1992-02-24 1995-02-14 Laboratoires Upsa Pyrazolopyrimidine derivatives which are angiotensin II receptor antagonists
TW237456B (es) * 1992-04-09 1995-01-01 Ciba Geigy
JPH0776542A (ja) 1993-09-06 1995-03-20 Canon Inc 液晶性化合物、これを含む液晶組成物、それを有する液晶素子、それらを用いた表示方法および表示装置
US5744492A (en) * 1993-09-17 1998-04-28 United States Of America Method for inhibiting angiogenesis
US5602156A (en) * 1993-09-17 1997-02-11 The United States Of America As Represented By The Department Of Health And Human Services Method for inhibiting metalloproteinase expression
IL112290A (en) 1994-01-12 1999-01-26 Novartis Ag Transformed aryl and the troiryl pyrimidines and herbicides containing them
GB9405347D0 (en) * 1994-03-18 1994-05-04 Agrevo Uk Ltd Fungicides
US5563143A (en) 1994-09-21 1996-10-08 Pfizer Inc. Catechol diether compounds as inhibitors of TNF release
US6057346A (en) * 1994-12-12 2000-05-02 The United States Of America As Represented By The Department Of Health And Human Services Inhibition of retroviral LTR promoters by calcium response modifiers
US5741818A (en) 1995-06-07 1998-04-21 University Of Saskatchewan Semicarbazones having CNS activity and pharmaceutical preparations containing same
ES2166462T3 (es) * 1995-08-02 2002-04-16 Smithkline Beecham Corp Antagonistas del receptor de la endotelina.
WO1998037068A1 (en) 1997-02-21 1998-08-27 Bristol-Myers Squibb Company Benzoic acid derivatives and related compounds as antiarrhythmic agents
JP2001526648A (ja) 1997-04-22 2001-12-18 コセンシス・インコーポレイテッド 炭素環及びヘテロ環で置換されたセミカルバゾン及びチオセミカルバゾン、及びその使用
BR9813468A (pt) 1997-12-12 2001-11-13 Abbott Lab Inibidores triazìnicos da angiogênese
JP4321737B2 (ja) 1997-12-17 2009-08-26 塩野義製薬株式会社 新規ピリジン化合物
WO1999032468A1 (en) 1997-12-19 1999-07-01 Takeda Chemical Industries, Ltd. Anilide derivative, production and use thereof
WO1999038829A1 (en) 1998-01-28 1999-08-05 Shionogi & Co., Ltd. Novel tricyclic compound
CA2352612A1 (en) 1998-11-27 2000-06-08 Hideo Fukui Pharmaceuticals
SK9162001A3 (en) 1998-12-24 2002-01-07 Aventis Pharm Prod Inc Substituted (aminoiminomethyl or aminomethyl)benzoheteroaryl compounds as factor xa inhibitors
IL145508A0 (en) * 1999-03-26 2002-06-30 Euro Celtique Sa Aryl substituted pyrazole, imidazole, oxazole, thiazole and pyrrole derivatives and pharmaceutical compositions containing the same
DOP2000000109A (es) 1999-12-23 2002-08-30 Gerald Kleymann Derivados de tiazolilamida
NZ520041A (en) 2000-01-20 2004-11-26 Eisai Co Ltd Novel piperidine compounds and drugs containing the same
AR029489A1 (es) * 2000-03-10 2003-07-02 Euro Celtique Sa Piridinas, pirimidinas, pirazinas, triazinas sustituidas por arilo, composiciones farmaceuticas y el uso de las mismas para la manufactura de un medicamento
RU2276141C9 (ru) * 2000-03-24 2006-08-27 Еро-Сельтик С.А. Арилзамещенные пиразолы или триазолы, фармацевтическая композиция, способ лечения, профилактики или снижения интенсивности различных нарушений или состояний у животного (варианты)
IL151952A0 (en) * 2000-03-31 2003-04-10 Euro Celtique Sa Aminopyridine derivatives and pharmaceutical compositions containing the same
JP4272338B2 (ja) 2000-09-22 2009-06-03 バイエル アクチェンゲゼルシャフト ピリジン誘導体

Also Published As

Publication number Publication date
JP2005501916A (ja) 2005-01-20
KR20040074973A (ko) 2004-08-26
HUP0500138A3 (en) 2005-07-28
EP1432424A1 (en) 2004-06-30
US20030073724A1 (en) 2003-04-17
CA2459531A1 (en) 2003-03-20
RU2004110725A (ru) 2005-10-10
HUP0500138A2 (hu) 2005-05-30
BR0212327A (pt) 2004-09-21
WO2003022285A1 (en) 2003-03-20
IL160714A0 (en) 2004-08-31
MXPA04002172A (es) 2004-07-23
US6770661B2 (en) 2004-08-03

Similar Documents

Publication Publication Date Title
AR036873A1 (es) Piridinas aril sustituidas a, composiciones farmaceuticas y el uso de las mismas para la preparacion de un medicamento
AR037233A1 (es) Piridinas aril sustituidas, composiciones farmaceuticas y el uso de dichos compuestos para la elaboracion de un medicamento
AR029489A1 (es) Piridinas, pirimidinas, pirazinas, triazinas sustituidas por arilo, composiciones farmaceuticas y el uso de las mismas para la manufactura de un medicamento
AR083339A1 (es) Compuestos de quinazolina como bloqueadores de los canales de sodio
AR061858A1 (es) Compuestos heterociclicos de fosfonatos y fosfinatos, composiciones farmaceuticas que los contienen y usos como agentes antidiabeticos.
TW375609B (en) 1-benzenesulfonyl-1,3-dihydro-indol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present
EA200500018A1 (ru) Бензконденсированные гетероариламидные производные тиенопиридинов, применяемые в качестве терапевтических агентов, фармацевтические композиции, включающие их, и способы их применения
GEP20125456B (en) Azetidines as mek inhibitors for the treatment of proliferative diseases
AR060545A1 (es) Compuestos de benzoaxol y benzotiazol 6-0- sustituidos y metodos de inhibicion de la senalizacion de csf-1r. composiciones farmaceuticas
PE20170775A1 (es) Derivados de benzodiazepina citotoxicos
MY136800A (en) Inhibitors of the interaction between mdm2 and p53
ATE289602T1 (de) Quinolin-2-on-derivate verwendbar als antikrebsmittel
TW430660B (en) Novel benzindole derivatives for neuron cell protection, processes for production, and the pharmaceutical compounds containing them
PL368409A1 (en) Derivatives of triazolyl-imidazopyridine and of the triazolylpurines useful as ligands of the adenosine a2a? receptor and their use as medicaments
AR047076A1 (es) Compuestos de pirrolotriazina como inhibidores de tirosina quinasas, composiciones farmaceuticas
IL108562A (en) 7, 8-diaryl-1,2,3,4- terahydropyrazolo- £5,1-c| £1,2,4| triazine derivatives, methods for the preparation thereof and pharmaceutical compositions containing them
WO2004020431A3 (en) Novel benzoimidazole derivatives useful as antiproliferative agents
MX2010000658A (es) Derivados de pirimidina 934.
CY1116183T1 (el) Πιπεραζινοδιονες ως ανταγωνιστες υποδοχεα οξυτοκινης
TR199801935T2 (xx) N�trofil elastaz inhibit�rleri olarak pirolopirolon t�revleri.
BG104717A (en) Water soluble azoles as broad-spectrum antifungals
HRP20080119T3 (en) Benzothiadiazine derivatives, method for preparing same and pharmaceutical compositions containing same
IL197513A0 (en) Pyrazolopyrimidine derivatives and pharmaceutical compositions containing the same
AR024146A1 (es) Derivados de 4-fenil-pirimidina
MXPA05010651A (es) Compuestos de pirazol.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal